SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ONXX -- Ignore unavailable to you. Want to Upgrade?


To: SemiBull who wrote (747)4/14/2002 4:26:45 PM
From: Skeet Shipman  Read Replies (2) | Respond to of 810
 
On February 28, Onyx management issued a letter to shareholders outlining a new business strategy, suspending development of Onyx-015 and shifting emphasis to BAY43-9006, an inhibitor of the raf-1 signaling pathway partnered with Bayer AG still in Phase I clinical trials.